Earnings Call for Q3FY21 of Sun Pharmaceutical Industries
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.29-01-2021
29-01-2021
Sun Pharma Q3 Profit Doubles To Rs 1,852.5 Crore
The pharma major reported a net profit of Rs 1,852.5 crore in Q3FY2129-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to financial results for the third quarter and nine-month ending December 31st, 2020,29-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action - Fixes Record Date For Interim Dividend
The Board at its meeting held today, declared an interim dividend of Rs. 5.50/- (Rupees Five and paise fifty only) per equity share of Re. 1/- each of the Company for the financial year ending on March 31, 2021. Further, the Board of Directors of the Company has fixed Wednesday, February 10, 2021 as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive payment towards Interim Dividend of the Company for the financial year 2020-21 declared today. The payment of the interim dividend would be made to the eligible shareholders on or before February 19, 2021.29-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action-Board approves Dividend
1)Approval of Unaudited Financial Statements for the quarter and nine months ended December 31, 2020; 2) Declaration of an Interim Dividend for the financial year ending on March 31, 2021 and fixing of Record Date for the same; and 3) Re-appointment of Mr. Kalyanasundaram Subramanian (DIN: 00179072) as Whole-time Director for further period of two years w.e.f. February 14, 2021.29-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Outcome Of Board Meeting
1) Approval of Unaudited Financial Statements for the quarter and nine months ended December 31, 2020; 2) Declaration of an Interim Dividend for the financial year ending on March 31, 2021 and fixing of Record Date for the same; and 3) Re-appointment of Mr. Kalyanasundaram Subramanian (DIN: 00179072) as Whole-time Director for further period of two years w.e.f. February 14, 2021.29-01-2021
Sun Pharma's profit, revenue to rise in Q3; EBITDA margin may remain stable
Brokerage firm Motilal Oswal Financial Services expects a 65.7 percent YoY rise in adjusted net profit and a 7.3 percent YoY rise in revenue for the quarter.29-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 28, 2021 for Raksha Sudhir Valia28-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 28, 2021 for Aditya Medisales Ltd28-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 27, 2021 for Shanghvi Finance Pvt Ltd27-01-2021